

Special Issue

Alzheimer's Disease Genetics

Message from the Guest Editors

- Genetic Variant Associations: Original research exploring the influence of specific rare and common genetic variants on Alzheimer's disease susceptibility and progression.
- Genetic Biomarkers: Papers elucidating the use of genetic markers for early diagnosis, disease risk assessment and personalized treatment strategies.
- Genetic Heterogeneity: Studies addressing the genetic heterogeneity of Alzheimer's disease and its implications for clinical practice.
- Epigenetics, Gene Regulation and Gene Expression: Investigations into epigenetic mechanisms, gene regulatory processes and transcriptomic studies that are relevant to Alzheimer's disease pathogenesis.
- Genetic Technologies: Articles focusing on how state-of-the-art technologies, including machine learning, improve Alzheimer's disease research.
- Emerging and Established Therapeutic Strategies: Reviews or original research discussing novel therapeutic interventions targeting the genetic aspects of Alzheimer's disease, or how genetics relate to already-approved (or soon to be approved) therapies.

Guest Editors

Dr. Laura Ibanez

1. Department of Psychiatry, Washington University in Saint Louis School of Medicine, 4444 Forest Park, Campus Box 8134, Saint Louis, MO, 63110, USA
2. NeuroGenomics and Informatics Center, Washington University in Saint Louis School of Medicine, Saint Louis, MO, 63110, USA
3. Department of Neurology, Washington University in Saint Louis School of Medicine, Saint Louis, MO, 63110, USA

Dr. Justin Miller

1. Department of Pathology and Laboratory Medicine, University of Kentucky, Lexington, KY, 40536 USA
2. Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY 40536, USA
3. Division of Biomedical Informatics, Department of Internal Medicine, University of Kentucky, Lexington, KY, 40536, USA
4. Department of Microbiology, Immunology, and Molecular Genetics, University of Kentucky, Lexington, KY, 40536 USA

Deadline for manuscript submissions

30 November 2024



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed



mdpi.com/si/190569

Biomedicines
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.3 days after submission; acceptance to publication is undertaken in 3.4 days (median values for papers published in this journal in the first half of 2024).